Vivimed Labs exports first shipment of Famotidine tablets to Canada
Vivimed Labs, an Indian pharma company, said that it has exported the first shipment of its Famotidine tablets 40mg and 20mg to Canada.
Famotidine is a histamine H2 receptor antagonist, which has been approved by Health Canada for the relief of heartburn, indigestion, stomach upset, sour stomach because of excess stomach acid, hyperacidity, and acid indigestion.
Apart from that Famotidine tablets are indicated in Canada for preventing the symptoms of excess stomach acid resulting from consuming certain food and/or beverages.
Vivimed Labs exports first shipment of Famotidine tablets to Canada. Photo courtesy of Free-Photos from Pixabay.
Ramesh Krishnamurthy – CEO of Vivimed Labs said: “Successful launch of Famotidine is a demonstration of Vivimed’s COMO capability to prestigious Canada market in collaboration with a highly respected strategic partner. This sets the stage for exciting new range of COMO products. In the next 6 months Vivimed shall continue to leverage end to end capabilities s to expand its COMO foot print.”
Earlier this month, Vivimed Labs launched Favulous, the company’s generic version of Covid-19 drug Favipiravir Tablet 200 mg and 400 mg in India.